SoluBest , a clinical stage company, has developed a proprietary nanotechnology platform for significantly improving the bio-performance of poorly soluble and insoluble drugs which have not lived up to their therapeutic potential due to delivery and/or compliance deficiencies.
The Company’s proprietary and versatile solubilization technology is widely applicable to numerous off-patent (or soon to be off-patent) drugs and new chemical entities (NCE's).
Rapid screening times allow the identification of suitable candidates in a few short weeks. Feasibility studies to clinical batch preparation can proceed in under 6 months.
A significant advantage of the technology stems from its use of readily available equipment for a process consisting of a few simple steps - making scale-up safe, robust, rapid and inexpensive.
The Company’s business strategy focuses on the development of novel drug formulations that can be performed in collaboration with API manufacturers, generic and brand pharmaceutical companies, biotechs and drug delivery firms.